Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Erlotinib + LY3499446 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Erlotinib | Tarceva | CP358774 | EGFR Inhibitor (Pan) 54 EGFR Inhibitor 1st gen 3 | Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (FDA.gov; PMID: 25302162). |
LY3499446 | LY-3499446|LY 3499446 | KRAS G12C inhibitor 18 | LY3499446 is an oral inhibitor of KRAS G12C that prevents constitutive downstream signaling to inhibit tumor cell proliferation and growth (PMID: 32014824). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04165031 | Phase Ib/II | Cetuximab + LY3499446 Erlotinib + LY3499446 LY3499446 Abemaciclib + LY3499446 Docetaxel | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | Terminated | USA | 1 |